Resources
6 Results (showing 1 - 6)
Results sorted by posted date (oldest first)
Results sorted by posted date (oldest first)
Posted 8/12/2020 (updated 3/28/2024)
The Recognizing and Addressing Rural Homeless in Opioid Use Disorder (OUD) Programs webinar took place Tuesday, August 04, 2020. The presentation and video recording are included.
Posted 10/14/2021 (updated 4/3/2024)
Stimulant intoxication, withdrawal, and psychosis have accepted and established treatment strategies. Several lifesaving harm reduction interventions/services are available. There are no Food and Drug Administration-approved medications for treatment of stimulant use disorder, although several are promising. Behavioral treatment, especially the use of contingency management (and other approaches with supportive evidence), has by far the best evidence of effectiveness. The presenter reviewed topics of importance to clinicians treating individuals with stimulant use disorder.
Rick Rawson, PhD, University of Vermont Rural Center of Excellence
Posted 3/21/2023 (updated 3/27/2024)
Training materials A Stimulating Talk
Posted 5/16/2023 (updated 3/27/2024)
Xylazine, a veterinary tranquilizer not approved for human use, has been increasingly identified in parts of the U.S. illicit drug supply.
Posted 7/26/2023 (updated 3/28/2024)
Rural communities are finding innovative ways to combat dual crises: an affordable-housing shortage and the overdose and substance misuse epidemic. This presentation highlighted (1) federally subsidized housing regulations related to affordable housing for residents with a history of SUD and (2) cross-sector approaches to providing housing and support services to residents in recovery.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.